6MK.F: Summary for MERCK CO. DL-,01 - Yahoo Finance

UK Markets closed

Merck & Co., Inc. (6MK.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
57.25-0.58 (-1.01%)
At close: 3:52PM CEST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous close57.83
Bid57.06 x 100000
Ask57.13 x 100000
Day's range56.97 - 57.49
52-week range46.76 - 63.31
Avg. volume920
Market cap160.85B
PE ratio (TTM)40.60
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Reuters3 days ago

    Bristol-Myers beats Wall St estimates, helped by cancer drug Opdivo

    Bristol-Myers Squibb Co on Thursday reported higher-than-expected quarterly earnings, helped by increased sales of cancer drugs Opdivo and Yervoy and blood thinner Eliquis. The U.S. drugmaker, which has faced increasing competition for blockbuster Opdivo as well as pressure from activist investors, also raised its full-year earnings outlook, reversing a cut it made in January. Opdivo sales jumped 60 percent in the first quarter, while Eliquis gained 50 percent and Yervoy rose 25 percent.

  • Reuters3 days ago

    Merck cholesterol drug Vytorin faces competition from Impax, Teva generics

    Merck & Co's cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announced progress on their generic versions of a drug that generated more than $1 billion in sales last year. The U.S. Food and Drug Administration on Wednesday approved Impax Laboratories Inc's generic version of Vytorin, while Teva Pharmaceutical Industries Ltd launched its generic version of the drug in the United States. Impax said it will immediately start commercialization for its generic version of Vytorin.

  • Reuters3 days ago

    FDA approves Impax generic of Merck's cholesterol drug Vytorin

    The U.S. Food and Drug Administration on Wednesday approved Impax Laboratories Inc's generic version of Merck & Co's cholesterol-reducing drug Vytorin, the first cheap competitor for a drug that in 2016 generated more than $1 billion in sales. Vytorin is a combination product that includes the drugs ezetimibe and simvastatin, sold under the brand names Zocor and Zetia. Zetia lost patent protection on Tuesday.